CS McKee’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

CS McKee’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$452K	Buy	+150,100	New	+$390K	0.04%	96

Other funds holding BMY.RT

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CS McKee's BMY.RT Position: Q4 2019 in Review

CS McKee opened a new position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2019: 150,100 shares worth $452K. The stake represents 0.04% of the portfolio and ranks #96 among its holdings.

616 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2019.

CS McKee held 150,100 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $452K as of Q4 2019.
Bristol-Myers Squibb Company Contingent Value Rights was a new CS McKee position in Q4 2019.
Bristol-Myers Squibb Company Contingent Value Rights made up 0.04% of CS McKee's portfolio in Q4 2019, its #96 holding.
616 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2019.

Based on CS McKee's 13F filing for Q4 2019, filed 14 Feb 2020.